Your browser is no longer supported. Please, upgrade your browser.
NVUS Novus Therapeutics, Inc. daily Stock Chart
Novus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own0.80% Shs Outstand9.32M Perf Week-5.17%
Market Cap39.33M Forward P/E- EPS next Y-1.37 Insider Trans86.05% Shs Float7.24M Perf Month-15.77%
Income-11.10M PEG- EPS next Q-0.40 Inst Own52.90% Short Float3.43% Perf Quarter-43.20%
Sales- P/S- EPS this Y81.40% Inst Trans- Short Ratio2.01 Perf Half Y-11.16%
Book/sh2.29 P/B1.84 EPS next Y0.70% ROA-47.70% Target Price10.13 Perf Year-5.59%
Cash/sh- P/C- EPS next 5Y- ROE-51.60% 52W Range3.12 - 8.61 Perf YTD3.94%
Dividend- P/FCF- EPS past 5Y6.80% ROI- 52W High-58.77% Beta0.44
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low13.78% ATR0.36
Employees8 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)30.73 Volatility9.70% 8.64%
OptionableNo Debt/Eq0.00 EPS Q/Q78.90% Profit Margin- Rel Volume0.41 Prev Close4.22
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume123.55K Price3.55
Recom1.50 SMA20-19.94% SMA50-24.08% SMA200-30.86% Volume23,684 Change-15.88%
Feb-13-18Initiated Ascendiant Capital Markets Buy $7
Sep-26-18 08:30AM  Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference Business Wire -6.07%
Sep-07-18 09:25AM  Novus Therapeutics to Postpone Offering of Common Stock Business Wire +19.42%
Sep-04-18 04:05PM  Novus Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Aug-07-18 08:30AM  Novus Therapeutics Reports Second Quarter 2018 Financial Results Business Wire
Jun-19-18 07:30AM  Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media Business Wire +8.00%
May-11-18 09:15AM  Novus Therapeutics Reports First Quarter 2018 Financial Results Business Wire +11.98%
Apr-02-18 09:00AM  Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update Business Wire -5.95%
Jan-05-18 07:20PM  Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)? Simply Wall St.
Nov-21-17 03:00PM  Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
12:49PM  Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)? Simply Wall St.
Nov-08-17 04:52PM  Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 04:01PM  Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President PR Newswire -6.56%
Oct-05-17 09:26AM  Whats The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)? Simply Wall St.
Aug-09-17 06:08PM  Novus Therapeutics Reports Second Quarter 2017 Results PR Newswire
Jul-10-17 06:30AM  Novus Therapeutics Announces Change in Management PR Newswire
Jun-12-17 08:00AM  Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TURKEL CATHERINE C.PresidentSep 12Buy5.0216,63283,47678,199Sep 13 08:00 PM
TURKEL CATHERINE C.PresidentSep 11Buy4.5617,04877,67161,567Sep 13 08:00 PM
TURKEL CATHERINE C.PresidentSep 05Buy3.978053,193805Sep 07 08:00 PM